SCI Ventures
SCI Ventures is a London-based evergreen venture philanthropy fund founded in 2023, the first specialist VC dedicated to curing paralysis. It invests globally at Seed and Series A into biotech and neurotechnology companies developing spinal cord injury therapies, backed by five leading global SCI foundations.
- Company typePrivate
- Founded2023
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What SCI Ventures does
SCI Ventures is a London-headquartered, evergreen venture philanthropy fund founded in 2023 as the first specialist venture vehicle dedicated to curing paralysis. It invests globally at Seed and Series A stages into biotech and neurotechnology companies developing therapies for spinal cord injury (SCI), spanning therapeutic peptides, small molecule drugs, gene therapies, brain-computer interfaces, electrical stimulation, and assistive technologies. The portfolio comprises eight companies including NervGen Pharma, Axonis Therapeutics, EG 427, and Precision Neuroscience.
The fund's structure is distinctive: it is co-created and underwritten by five leading global SCI foundations (Christopher & Dana Reeve Foundation, Shepherd Center, Spinal Research, Wings for Life, Promobilia Foundation), with the Reeve Foundation covering all initial operating costs so that 100% of returns and donated capital can be reinvested into the portfolio. Governance combines an Investment Committee staffed by senior ex-VC/CIO operators (BC Partners, 3i, Jefferies, Lazard, PwC) with a Scientific Advisory Council of leading academic neuroscientists and SCI clinicians. SCI Ventures' competitive position rests on exclusive access to foundation networks, patient communities, and standardized pre-clinical pipelines that no generalist VC replicates.
Commercially, SCI Ventures targets an addressable population of 15 million people worldwide living with SCI, where average lifetime care costs reach $4 million and typical onset is under age 39. The fund has catalyzed over $500 million in follow-on capital from top-tier VCs into its portfolio companies and has expanded into AI-assisted drug discovery via a partnership with Healx, while adding Craig Hospital as a sixth alliance partner with board representation.
SCI Ventures firmographics
Firmographics- Name
- SCI Ventures
- Legal name
- SCI Ventures
- Website
- https://sciventures.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SCI Ventures is a London-based evergreen venture philanthropy fund founded in 2023, the first specialist VC dedicated to curing paralysis. It invests globally at Seed and Series A into biotech and neurotechnology companies developing spinal cord injury therapies, backed by five leading global SCI foundations.
- Ownership category
- akta.pro rank
SCI Ventures industry classification
Industry- Product category
- Venture Capital / Healthcare Impact Investing
- NAICS
- Other Investment Pools and Funds (5259)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Venture Capital Fund-of-Funds (FSANAGAC)
- akta.pro secondary industries
- Research & Science Grantmaking Foundations (BPAGAKAI), Health & Medical Research Grantmaking Foundations (BPAGAKAL)
Keywords
Where SCI Ventures is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
SCI Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Others
Revenue model
- Investment Returns: SCI Ventures operates as an evergreen fund where all investment returns are recycled and reinvested within the fund to take more targeted shots at curing paralysis. The fund makes investments with the intent of generating a financial return while catalyzing therapies for spinal cord injury.
Distribution channels1 record
Marketing channels3 records
SCI Ventures product offering
Product offeringCore offering
SCI Ventures is an evergreen venture philanthropy fund that invests in early-stage biotech and neurotechnology companies developing cure-oriented therapies for spinal cord injury and paralysis, typically at Seed and Series A stages. The fund provides capital, clinical expertise, and patient community connections, with all returns recycled and reinvested within the fund to catalyze cures for paralysis.
Product overview
SCI Ventures is an evergreen venture philanthropy fund dedicated to catalyzing innovative cures for paralysis. The fund invests in early-stage companies developing cure-oriented therapies for spinal cord injury and related neurological conditions, typically at Seed and Series A stages. Backed by leading foundations including the Christopher & Dana Reeve Foundation, Shepherd Center, Spinal Research, Wings for Life, and Promobilia Foundation, the fund provides capital as well as clinical expertise and patient community connections to support portfolio companies. All returns are recycled and reinvested within the fund to take more targeted shots at the goal of curing paralysis. The fund's portfolio spans therapeutic peptides, small molecule drugs, gene therapies, brain-computer interfaces, electrical stimulation, and assistive technologies.
Differentiator
Problem solved
Functional benefit
Products and services
- SCI Ventures Evergreen Fund
Companies that use SCI Ventures
Customer profileSegments1 record
Ideal customer profiles1 record
SCI Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
SCI Ventures partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- Craig HospitalflagshipCraig Hospital, a nationally recognized neurorehabilitation hospital specializing in spinal cord and brain injury care, has joined SCI Ventures as an Alliance Partner. The partnership includes an investment in the fund and representation on the board of directors. Craig Hospital contributes clinical expertise and direct patient community connections to advance the fund's mission of bringing new therapies to persons living with paralysis.
- HealxcoreSCI Ventures partnered with Healx to create a neuro-regeneration program with a focus on chronic spinal cord injury. Healx contributes its AI platform for drug discovery to identify novel therapeutic targets and match them with repurposable drugs for accelerated development of treatments for the 20 million people globally affected by paralysis.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
SCI Ventures competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
SCI Ventures compliance and trust
Trust signalCompliance1 record
SCI Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
SCI Ventures leadership team
Management profileNumber of profiles
Profiles11 records
SCI Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SCI Ventures M&A and investment
M&A and investmentM&A
Investments8 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SCI Ventures
What does SCI Ventures do?
SCI Ventures is an evergreen venture philanthropy fund that invests in early-stage biotech and neurotechnology companies developing cure-oriented therapies for spinal cord injury and paralysis, typically at Seed and Series A stages. The fund provides capital, clinical expertise, and patient community connections, with all returns recycled and reinvested within the fund to catalyze cures for paralysis.
Is SCI Ventures a public or private company?
SCI Ventures is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was SCI Ventures founded?
SCI Ventures was founded in 2023. It employs 1 to 10 people.
Where is SCI Ventures based?
SCI Ventures is headquartered in London, United Kingdom, in the Europe region.
How does SCI Ventures make money?
One revenue line is on record: investment Returns.
Does SCI Ventures have an API?
No public API is recorded for SCI Ventures.
What industry is SCI Ventures in?
SCI Ventures's product category is Venture Capital / Healthcare Impact Investing. Its primary akta.pro industry code is FSANAGAC, Venture Capital Fund-of-Funds, with a secondary code of BPAGAKAI, Research & Science Grantmaking Foundations. Its NAICS code is 5259 and its SIC code is 6282.